Last reviewed · How we verify

LIQ865B bupivacaine formulation

Liquidia Technologies, Inc. · Phase 1 active Small molecule

LIQ865B bupivacaine formulation is a Small molecule drug developed by Liquidia Technologies, Inc.. It is currently in Phase 1 development. Also known as: Marcaine, Marcaine Spinal, Sensorcaine, Sensorcaine-MPF.

At a glance

Generic nameLIQ865B bupivacaine formulation
Also known asMarcaine, Marcaine Spinal, Sensorcaine, Sensorcaine-MPF, Sensorcaine-MPF Spinal
SponsorLiquidia Technologies, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about LIQ865B bupivacaine formulation

What is LIQ865B bupivacaine formulation?

LIQ865B bupivacaine formulation is a Small molecule drug developed by Liquidia Technologies, Inc..

Who makes LIQ865B bupivacaine formulation?

LIQ865B bupivacaine formulation is developed by Liquidia Technologies, Inc. (see full Liquidia Technologies, Inc. pipeline at /company/liquidia-technologies-inc).

Is LIQ865B bupivacaine formulation also known as anything else?

LIQ865B bupivacaine formulation is also known as Marcaine, Marcaine Spinal, Sensorcaine, Sensorcaine-MPF, Sensorcaine-MPF Spinal.

What development phase is LIQ865B bupivacaine formulation in?

LIQ865B bupivacaine formulation is in Phase 1.

Related